ArticleHemaSphere2025

Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).

Luca De Carolis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.